# A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

> **NCT05183958** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 118 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **RADIATION:** Radiotherapy group
- **DRUG:** Camrelizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05183958
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-31
- **Primary completion:** 2023-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183958, "A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05183958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*